Congress mandates Alzheimer's blood tests for all insured Americans

What it does

This bill requires private health insurance plans and Medicaid to cover Alzheimer's biomarker testing (blood tests and genetic analysis that detect early signs of Alzheimer's disease) without restrictive cost-sharing, prior authorization delays, or step-therapy requirements. It applies the same coverage rules to all insurance types and mandates equitable access for rural and underserved populations, with a one-year implementation window.

Why we flagged it

The bill's core mechanism is a coverage mandate — it requires insurers and Medicaid to pay for a specific diagnostic service without cost-sharing or procedural barriers. This is a regulatory expansion of insurance obligations, not a tax measure, subsidy, or deregulation.

What the text implies

• Biomarker testing definition is broad and includes emerging tests (whole genome/exome sequencing) not yet FDA-approved, potentially creating coverage obligations for tests still in development or with unclear clinical utility.
• The bill ties coverage to 'applicable clinical practice guidelines or consensus statements' without specifying which organizations set these standards, creating potential for industry-captured guideline bodies to expand covered tests beyond evidence-based scope.
• Mandatory coverage without cost-sharing may increase demand for biomarker testing, benefiting diagnostic companies and labs; insurers will absorb costs, which may be passed to other policyholders through premium increases.
• The 72-hour (or 24-hour) prior-authorization window and deemed-approval provision may pressure insurers to approve requests without full clinical review, shifting gatekeeping burden from insurers to providers.
• Medicaid coverage mandate creates unfunded state obligation; states must cover testing or face federal penalties, but the bill does not appropriate funds to offset state Medicaid costs.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

Ordinary people gain earlier access to diagnostic testing that may enable earlier treatment of Alzheimer's disease, with reduced financial and procedural barriers. The bill removes cost-sharing discrimination and prior-authorization delays, lowering out-of-pocket costs and speeding diagnosis for insured populations.

Who stands to gain

• diagnostic laboratory companies
• biomarker test manufacturers
• genetic testing firms
• healthcare IT vendors (prior-auth systems)
• clinical laboratory networks

Named in the bill

JNJ (Johnson & Johnson), BMY (Bristol Myers Squibb), AIG (American International Group), FBK (Feedback Inc.), PRU (Prudential Financial), FDA (Food and Drug Administration), NIH (National Institutes of Health), National Academies of Sciences, Engineering, and Medicine, Medicaid, Public Health Service Act, Social Security Act

Where it stands

2 cosponsors: 2 Republicans.

• Jul 22, 2026 — Introduced · Congress.gov: “Introduced in House”
• Jul 22, 2026 — Referred to House Committee on Energy and Commerce · Congress.gov: “Referred to the House Committee on Energy and Commerce”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.